Can-Fite BioPharma American Depositary Shares
CANF
8 hedge funds and large institutions have $1.59M invested in Can-Fite BioPharma American Depositary Shares in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
33% more funds holding
Funds holding: 6 → 8 (+2)
6% more capital invested
Capital invested by funds: $1.5M → $1.59M (+$88K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$36.5K |
| 2 |
VF
Virtu Financial
New York
|
+$13.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$18.3K |
| 3 |
PCM
Prelude Capital Management
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TAM
1
Taylor Asset Management
Toronto,
Ontario, Canada
| $1.19M | – | – | – |
|
|
MIH
2
Meitav Investment House
Bene-Beraq,
Israel
| $240K | +$238K | +52 | New |
|
|
3
Morgan Stanley
New York
| $97K | +$36.5K | +8 | +57% |
|
|
VF
4
Virtu Financial
New York
| $29K | +$13.7K | +3 | +75% |
|
|
RJA
5
Raymond James & Associates
St Petersburg,
Florida
| $18K | – | – | – |
|
|
WWMSC
6
Wagner Wealth Management (South Carolina)
Greenville,
South Carolina
| $12K | +$9.14K | +2 | New |
|
|
AF
7
Advisornet Financial
Minnetonka,
Minnesota
| $5K | +$4.57K | +1 | New |
|
|
PVH
8
Psagot Value Holdings
Tel Aviv,
Israel
| $4K | -$18.3K | -4 | -80% |
|
9
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$20K | -4 | Closed |
|
|
PCM
11
Prelude Capital Management
New York
| – | -$2K | – | – |
|
CANF Hedge Fund Activity: Q4 2017 in Review
8 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q4 2017, worth a combined $1.59M — up 5.9% from $1.5M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CANF positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $36.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $20K sold.
- 8 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q4 2017, up from 6 in Q3 2017.
- Funds reported $1.59M of Can-Fite BioPharma American Depositary Shares stock for Q4 2017, up 5.9% quarter-over-quarter.
- 3 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q4 2017 and 1 closed out, a net change of +2 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q4 2017 was Morgan Stanley, an estimated $36.5K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q4 2017 was Citadel Advisors, an estimated $20K sold.
Based on aggregated 13F filings for Q4 2017.